CJC-1295 ACL and Ligament Rehabilitation Protocol: Dosing, Timeline, and Evidence
At a glance
- Generic name / CJC-1295, a GHRH(1-29) analogue (also called Mod GRF 1-29 in its non-DAC form)
- Drug class / Growth hormone-releasing hormone (GHRH) analogue, not GH itself
- Common forms / CJC-1295 without DAC (short-acting) and CJC-1295 with DAC (long-acting, albumin-bound)
- FDA status (as of 2025) / Not FDA-approved for any indication; may be available only through compounding pharmacies where regulatory status permits, and this changes over time
- Evidence for ACL/ligament repair specifically / No completed clinical trial; mechanistic and cross-population inference only
- Direct clinical evidence that does exist / One published phase 2 pharmacokinetic/pharmacodynamic trial in healthy adults; separate trials of GH (not CJC-1295) in GH-deficient adults showing effects on tendon collagen turnover
- Key uncertainty / Whether raising systemic IGF-1 with a GHRH analogue translates into faster or stronger ACL graft healing in humans is untested
The direct answer
CJC-1295 raises pulsatile growth hormone secretion and downstream IGF-1 levels through a well-described endocrine mechanism, and IGF-1 is known to influence collagen synthesis in tendon and ligament tissue. That mechanistic chain is real, but it has not been tested end-to-end in ACL patients: there is no published trial measuring graft strength, re-rupture rate, or return-to-sport time in humans given CJC-1295 after ACL surgery. The clinical practice of using CJC-1295 for ACL rehabilitation is an off-label extrapolation from GH-axis biology, not a guideline-supported or trial-proven protocol, and it carries real monitoring requirements around IGF-1, glucose, and cardiovascular effects that a prescribing physician needs to manage individually.
What CJC-1295 is, and what it is not
CJC-1295 is a synthetic 29 or 30-amino-acid analogue of endogenous GHRH. It binds the pituitary GHRH receptor and increases the amplitude of natural GH pulses, which secondarily raises hepatic IGF-1 production. It is not growth hormone itself, and it is not the same molecule as growth hormone secretagogues that act on the ghrelin receptor (such as ipamorelin), even though the two classes are frequently combined in off-label protocols.
Two forms circulate under this name:
- CJC-1295 without DAC (Mod GRF 1-29): a short-acting analogue with a plasma half-life on the order of minutes, intended to produce a GH pulse that resembles the body's own nocturnal pattern.
- CJC-1295 with DAC (Drug Affinity Complex): binds circulating albumin, extending its half-life to multiple days and allowing less frequent dosing, at the cost of a flatter, more tonic GH elevation rather than a physiologic pulse.
Neither form is FDA-approved for any indication as of 2025. Where compounded CJC-1295 remains accessible depends on FDA compounding policy for bulk drug substances, which has tightened for several peptides in recent years; a reader considering this should verify current status directly with a prescribing physician and pharmacy rather than relying on this article's regulatory description staying current (FDA compounding laws and policies).
What the evidence actually establishes, versus what is plausible but unproven
Established: GHRH analogues like CJC-1295 increase GH pulse amplitude and serum IGF-1 in humans. This has been shown in pharmacokinetic and pharmacodynamic studies in healthy adults. IGF-1 is a recognized mediator of collagen synthesis and fibroblast activity in connective tissue generally, and GH replacement has been studied in GH-deficient adults with measurable effects on tendon collagen turnover.
Plausible but unproven: That raising IGF-1 with CJC-1295 during ACL graft healing improves graft incorporation, reduces quadriceps atrophy, or shortens return-to-sport timelines in humans. This is a reasonable mechanistic hypothesis built from adjacent evidence (GH-deficient adult tendon physiology, animal ligament and tendon healing models), but no one has run the ACL-specific human trial.
Not established: Any specific magnitude of benefit for ACL healing, any specific re-rupture rate reduction, or a defined dose-response relationship for CJC-1295 in orthopedic rehabilitation. Numeric claims of this kind that circulate in peptide-clinic marketing material are not supported by the primary literature currently available to this review and should not be treated as verified until an editor can trace them to a specific, checkable source.
A note on sourcing: this draft intentionally does not carry forward several PubMed identifiers and precise percentage figures that appeared in an earlier version of this page, because those identifiers and numbers could not be verified against the underlying papers during this review. Where a claim needed a specific citation and none could be confirmed, the claim has been narrowed to a general description (for example, "a rodent tendon-healing study" rather than a named journal, year, and effect size) or removed. A qualified reviewer should trace and re-attach verified primary sources before publication.
Should CJC-1295 be started immediately after ACL surgery?
No. The acute inflammatory phase after ACL reconstruction, roughly the first two to three weeks, involves neutrophil and macrophage activity that helps clear debris and initiate the repair cascade. Practitioners who use CJC-1295 off-label in this setting typically wait until the acute inflammatory window has passed, generally two to three weeks post-operatively, before starting a GH-axis peptide, out of concern that elevating IGF-1 too early could interfere with the initial inflammatory signaling rather than support it. This sequencing is standard sports-medicine peptide practice, not a result derived from a controlled trial comparing early versus delayed initiation.
During this early phase, standard post-surgical care (surgeon-directed pain management, protected weight-bearing, passive range-of-motion work) continues regardless of any peptide decision.
What an off-label protocol typically looks like, and its limits
The pattern below reflects what is commonly described in off-label sports-medicine peptide prescribing. It is not an FDA-cleared regimen, it is not a personalized dosing instruction, and it should not substitute for a plan built with a prescribing physician who has the patient's labs, surgical details, and comorbidities in front of them.
| Phase | Typical window | Form used | What practitioners commonly report |
|---|---|---|---|
| Hold | Weeks 0-2 to 3 post-op | None | No CJC-1295; standard post-surgical care only |
| Proliferative | Weeks 2-3 to ~12 | CJC-1295 without DAC | More frequent dosing (several times weekly), often at bedtime, to preserve a pulsatile GH pattern; sometimes paired with a ghrelin-receptor agonist such as ipamorelin |
| Remodeling/maintenance | Weeks ~12 to 24 | CJC-1295 with DAC | Less frequent dosing (roughly weekly) for simplicity over a longer maintenance period |
Reported dose ranges in the low hundreds of micrograms per injection for the non-DAC form, and low milligrams weekly for the DAC form, appear repeatedly across off-label sources, but no controlled dose-ranging study in an ACL population exists to confirm these are optimal or even necessary doses. A physician managing an individual patient may reasonably choose a different schedule based on labs, tolerance, and concurrent medications.
Return-to-sport decisions should rest on standardized functional testing (limb symmetry index on quadriceps strength and hop testing is widely used in ACL rehabilitation), not on a calendar date or a peptide cycle length. Graft ligamentization, the biological remodeling of a tendon graft into ACL-like tissue, is understood to take well over a year regardless of any peptide intervention; a 24-week peptide cycle covers only the earlier part of that process.
Monitoring: what a physician managing this should be tracking
Because CJC-1295 acts on an endocrine axis with systemic effects, monitoring is not optional and should not be self-managed. The following describes what physicians experienced with GH-axis peptides typically monitor. It is general information, not a substitute for individualized lab targets set by the prescribing clinician.
Before starting: serum IGF-1, fasting glucose and HbA1c, a comprehensive metabolic panel, lipid panel, sex hormone panel, and thyroid function. Patients with pre-existing prediabetes or diabetes need this conversation before, not after, starting.
While on therapy: periodic IGF-1 rechecks, fasting glucose monitoring (more frequent in anyone with impaired glucose tolerance), periodic HbA1c, and blood pressure checks, since GH-related sodium retention can affect blood pressure in susceptible individuals.
Why this matters: GH is counter-regulatory to insulin, so IGF-1 elevation can worsen insulin sensitivity in some patients. IGF-1 is also a mitogenic signal, and sustained elevation of IGF-1 has been associated with increased cancer risk in population-level observational research, which is why active malignancy or a personal history of hormone-sensitive cancer is treated as a contraindication by clinicians using this class of peptide, and why nobody should be self-titrating toward "higher IGF-1 is better."
Who should not use CJC-1295
Clinicians experienced with GH-axis peptides generally avoid CJC-1295 in:
- Active malignancy or a personal history of hormone-sensitive cancer
- Uncontrolled diabetes
- Pregnancy or breastfeeding, where no safety data exist
- Anyone under 18, given open growth plates and an already-active endogenous GH axis
- Acromegaly or known pituitary adenoma
Controlled type 2 diabetes is not an automatic exclusion but requires closer glucose monitoring and a conversation about whether diabetes medication doses might need adjustment.
When to escalate to urgent care rather than wait for the next lab check
Persistent joint swelling with fever, calf pain or swelling suggestive of a blood clot, sudden severe headache or vision change, or new chest pain or shortness of breath are not peptide side effects to monitor at the next scheduled visit. These warrant urgent evaluation regardless of whether they might be related to CJC-1295, the surgery, rehabilitation activity, or something unrelated.
Clinician-conversation and monitoring framework
This is a structure for the conversation between a patient and prescribing physician, not a self-directed checklist. It separates what a general protocol can tell a reader from what only an individualized clinical relationship can decide.
| Checkpoint | What to bring to the visit | Reasonable to continue if | Reason to pause and re-evaluate | Reason to stop and escalate |
|---|---|---|---|---|
| Before starting | Surgical details, current medications, personal/family cancer and diabetes history, baseline labs (IGF-1, glucose, HbA1c, metabolic panel) | Labs are within normal range, no contraindication present, surgeon has cleared the current rehab phase | Baseline IGF-1 already near the upper limit of normal, or HbA1c in the prediabetic range | Active malignancy, uncontrolled diabetes, pregnancy, or acromegaly/pituitary disease identified |
| ~6 weeks in | IGF-1 recheck, fasting glucose, blood pressure trend, injection-site review, subjective sleep and swelling changes | IGF-1 has risen but remains within the upper part of the normal reference range, glucose stable, no new symptoms | IGF-1 trending toward the top of or above the normal range, glucose drifting upward | New or worsening joint swelling with systemic symptoms, uncontrolled blood pressure rise, or signs of a blood clot |
| ~12 weeks in (phase transition decision) | HbA1c, IGF-1, physical therapy progress notes, functional testing if available | Rehab milestones on track, labs stable, patient tolerating current form and dose | Rehab progress stalled despite adequate physical therapy, unclear whether peptide is adding value | Any red-flag symptom above, or labs outside the range the prescribing physician set as an individual threshold |
| Return-to-sport window | Formal limb symmetry index / functional testing results, not calendar time alone | Functional testing meets the threshold the surgeon and physical therapist use for that sport and patient | Functional testing below threshold regardless of peptide cycle length or calendar week | Any new injury symptom; functional testing failure should delay clearance regardless of peptide status |
The physician, not the protocol, sets individual thresholds for IGF-1, glucose, and blood pressure, because "normal" ranges shift with age, sex, and pre-existing conditions. A general article can describe the categories to monitor; it cannot set a safe number for a specific patient.
Regulatory and competitive-use status
CJC-1295 is not FDA-approved for any indication. As of 2025, access in the United States depends on compounding pharmacy regulations that have been narrowing for several peptides; a patient or clinician should verify current bulk-substance status directly with FDA compounding guidance and the dispensing pharmacy rather than assuming any particular access pathway remains open (FDA compounding laws and policies).
Peptide hormones and growth factor mimetics of this general class are commonly prohibited under anti-doping rules for tested athletes. Anyone competing in a tested sport should check current anti-doping rules with their sport's governing body before using any GH-axis peptide, since a therapeutic use exemption for an orthopedic rehabilitation indication is not something this article can predict.
Combining with other rehabilitation peptides
Some off-label protocols pair CJC-1295 with other peptides such as BPC-157 or thymosin beta-4 fragments (TB-500), reasoning that these act through different mechanisms (nitric oxide and VEGF signaling, actin polymerization) rather than the GH axis. Evidence for any of these combinations in ACL patients is observational and anecdotal at the clinic level; there is no controlled trial establishing that combination therapy outperforms either peptide alone, or that it is safe in combination, in an ACL population specifically. A reader interested in this should treat it as an open question to raise with a prescribing physician, not a validated stack.
Where verification is still needed before this page can carry stronger claims
Several claims that commonly appear in peptide-clinic marketing about CJC-1295 and ACL rehabilitation, including specific percentage improvements in tendon strength, specific re-rupture rate reductions tied to peptide use, and specific quadriceps atrophy figures, could not be traced to a verifiable primary source during this review and have been removed or generalized rather than repeated. A qualified medical reviewer with direct access to the primary orthopedic and endocrine literature should confirm or correct the general statements above before this page is treated as citable for specific numbers.
Frequently asked questions
Is there a clinical trial proving CJC-1295 helps ACL healing?
What is the difference between CJC-1295 with DAC and without DAC?
When do practitioners typically start CJC-1295 after ACL surgery?
What labs should someone on CJC-1295 be monitoring?
Who should not use CJC-1295?
Is CJC-1295 legal for competitive athletes?
Is CJC-1295 FDA-approved?
References
- US Food and Drug Administration. Compounding: 503A and 503B overview. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
A primary-source discovery search for this specific topic returned no verifiable results at the time of this draft. The numbered study citations, specific effect sizes, and named trials that appeared in an earlier version of this page could not be confirmed against the underlying literature during this review and have been removed or converted into general, unattributed descriptions pending verification by a qualified medical reviewer with direct literature access.